Home Stocks BMY Bristol-Myers Squibb Company (NYSE: BMY) Healthcare · Drug Manufacturers - General
— —
Quote unavailable · Price data is temporarily unavailable.
The Quantellect read. Short interest is 2.30% of float with a 0.41% borrow fee. Descriptive summary of the data on this page, not a recommendation.
Momentum Neutral RSI (14) 51.5 (overbought above 70, oversold below 30)
Short interest 2.3% of float FINRA settlement Oct 30, 2026
BMY price chart Price — · As of —
SMA 10 — SMA 20 — SMA 50 — SMA 200 —
Price details unavailable for this range. ×
Chart loads when this section enters view.
Dated chart events require JavaScript on this compact chart. Open the full chart for dated events .
Text price and event history 6M plotted price range (ET) Range 6M First date — Last date — Open — High — Low — Close — Volume — Plotted bars 0
Plotted OHLCV bars No price bars are available for this range.
Event records Event records load after the price chart.
Split-adjusted daily prices · Price as of —
Initial 6M price range summary Range 6M First close — Last close — High — Low — Volume —
Open —
Previous close —
Day range —
52-week range $44.79 – $68.09 Through Nov 18, 2026
Volume —
Average volume (30 calendar days, 0 sessions) — Through Nov 18, 2026
Market cap $129.66B
P/E (TTM) 14.1
Forward P/E 9.5
EPS (TTM) $4.51
Dividend yield 4.0%
Beta (5-year monthly vs SPY) 0.21
Price history BMY · NYSE · USD
Split-adjusted · volume in shares
Price history unavailable Retry
Notable price movement — · Notable price movement not available
Options flow — · Options flow not available
Q Score — · Q Score not available
Quantellect signals Change since Nov 18 Insufficient data · Observed Nov 16, 2026, 8:33 AM ET
Social Pulse 5 mentions in 24h
How the scores work → Industry comparison — · Industry comparison not available
Upcoming events — · Upcoming events not available
Analyst consensus — · Analyst consensus not available
Earnings history — · Earnings history not available
News and press releases News and press releases are not available.
All BMY news → Company profile Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic
CEO Dr. Christopher S. Boerner Ph.D.
Headquarters Princeton, NJ, United States
Employees 32,500
IPO date Jan 1, 1972
Sector Healthcare
Industry Drug Manufacturers - General Q Score — · Q Score not available
Quantellect signals Change since Nov 18 Insufficient data · Observed Nov 16, 2026, 8:33 AM ET
Social Pulse 5 mentions in 24h
How the scores work → Upcoming events — · Upcoming events not available
Analyst consensus — · Analyst consensus not available
Earnings history — · Earnings history not available
Company profile Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic
CEO Dr. Christopher S. Boerner Ph.D.
Headquarters Princeton, NJ, United States
Employees 32,500
IPO date Jan 1, 1972
Sector Healthcare
Industry Drug Manufacturers - General